近日，美国《临床肿瘤学杂志》（Journal of Clinical Oncology）发表了题为：Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial的研究。该研究评估了德曲妥珠单抗在选择的局部晚期、转移性或不可切除HER2过表达实体肿瘤患者中的疗效和安全性。